Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Stock Price, Quote & AI Analysis

Live ELDN stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Eledon Pharmaceuticals, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Eledon Pharmaceuticals, Inc. Common Stock (ELDN), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

ELDN
Eledon Pharmaceuticals, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
2.240000
High
2.250000
Low
2.110000
Volume
1,094,673
VWAP
-
Market Cap
$175,186,653.40
52W Range
$1.35 - $4.60
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Mar 18, 2026 Q4
After Hours
EPS Estimate: $-0.204
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Eledon Pharmaceuticals, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Eledon Pharmaceuticals, Inc. Common Stock Overview

Company information

Company Overview

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. The company was founded on March 26, 2004 and is headquartered in Irvine, CA.

Company Details
Market Cap
$164.44M
Shares Outstanding
75,084,700
Weighted Shares Outstanding
79,630,297
CEO
David-Alexandre C. Gros
Address
19800 MACARTHUR BLVD., IRVINE, CA, 92612
Employees
31
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Eledon Pharmaceuticals, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...